©2020 by HALO Diagnostics

LUNG CANCER SCREENING

 

WHY SCREEN FOR LUNG CANCER?

  • Lung cancer kills more people each year than colon, breast and prostate cancers combined 

  • Early detection and diagnosis improves the chances of lung cancer cure through treatment 

  • Ensures timely management and treatment of the condition

WHO SHOULD CONSIDER SCREENING?

According to the Lung Cancer Screening Guidelines (US Preventive Services Task Force, USPSTF)

  • Individuals between the ages of 55-80 years

  • 30 pack year or more of smoking history

  • Current smoker or has quit within the last 15 years


Lung cancer screening is most beneficial for individuals who are generally in good health and have no signs or symptoms of lung cancer


Individuals who may additionally benefit:

  • Patients with a history of lung cancer (treated >5 years ago), or individuals at an increased risk of lung cancer

  • Individuals with chronic obstructive pulmonary disease (COPD) and occupational hazards (exposure to asbestos) may benefit 

 

FOR MORE INFORMATION

We are always here for you! Contact us to schedule an appointment or to talk to one of our clinicians.
EMAIL at contact@halodx.com

Is your current age between 55-80 years?
Are you a current smoker or have quit smoking in last 15 years?
Do you have a 30-pack year or more smoking history? (1 pack year = 1 pack or 20 cigarettes/ day for 1 year)
Do you have lung cancer or have any signs/ symptoms indicating lung cancer?
 

References: Smoking cessation and lung health benefits

Impact of low-dose CT screening on smoking cessation among high-risk participants in the UK Lung Cancer Screening Trial

Brain, et al. Thorax 2017;72:912–918


Screening findings requiring follow-up may raise quit rates:

“The Danish Lung Cancer Screening Trial (DLCST) reported smoking cessation rates of almost 12% in both trial arms at 1 year follow-up, compared with the Danish population rate of 4%.  Quit rate was significantly higher in smokers who had a positive CT result that required repeat scans.”

“In the Dutch-Belgian NELSON Trial, the overall quit rate at 2 years follow-up was 16.6% compared with a background population rate of 3–7%.”

“The US National Lung Screening Trial (NLST) found that compared with normal lung screening results, receiving any screen-detected abnormality significantly reduced the probability of continued smoking.” 

 

FILES

Download Now

FILE NAME

This is your File description. Concisely describe the content of your file and make sure to highlight your contact details for further questions and remarks.

FILE NAME

This is your File description. Concisely describe the content of your file and make sure to highlight your contact details for further questions and remarks.